FDB (First Databank, Inc.) published a blog post by David Berkowitz, PharmD on how barcode verification, gravimetric analysis, and medication intelligence can help prevent high-risk compounding errors.
Public source
Publisher name
Public post
Sterile compounding is a critical point in the medication-use process, and one where layered safeguards can make a meaningful difference. Read David Berkowitz, PharmD’s…
Company
FDB (First Databank, Inc.)
The leading provider of drug and medical device knowledge that helps healthcare professionals make precise decisions.
- Industry
- Hospitals and Health Care
- Location
- South San Francisco, US
- Company size
- 201–500 employees
About FDB (First Databank, Inc.)
FDB (First Databank) creates and integrates the world’s most trusted drug knowledge that, in partnership with our customers, illuminates critical healthcare decisions. Together, we help improve patient safety, operational efficiency, and health outcomes. Our drug databases drive healthcare information systems that serve the majority of hospitals, physician practices, pharmacies, payers, and all other areas of healthcare and are used by millions of clinicians, business associates, and patients every day. For a complete look at FDB’s solutions and services, please visit https://www.fdbhealth.com.
See moreLatest activity
Latest activity from FDB (First Databank, Inc.)
10 signals
Research & Knowledge
FDB (First Databank, Inc.) published Brian Nowosielski's report on AI adoption in pharmacies for Drug Topics.
People
FDB (First Databank, Inc.) is hiring a new Brand Communications Manager in Carmel, Indiana.
People
FDB (First Databank, Inc.) is hiring a new Brand Communications Manager in San Francisco, California.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
FDB UK
FDB UK published an OptimiseRx factsheet examining patient-specific prescribing support to identify older people at higher risk of polypharmacy and medicine-related harm.
Research & Knowledge
ASHP
ASHP announced recent and anticipated novel drug approvals for Q2 2026 through Q1 2027, with the latest approvals available via AJHP.
Research & Knowledge
Clarest Health
Clarest Health published a full analysis of the 2026 Star Ratings and Part D CMR completion rate returns for the 2029 Star Ratings.
Research & Knowledge
PlumGxP
PlumGxP published an article examining recent FDA Form 483 observations and the practical steps for 503B facilities to strengthen microbiology and sterility-assurance programs.
Research & Knowledge
Serve You Rx